Status:
RECRUITING
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Lead Sponsor:
Deciphera Pharmaceuticals, LLC
Conditions:
Renal Cell Carcinoma
Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic...
Eligibility Criteria
Inclusion
- Key
- Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes
- Key
Exclusion
- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days of the first dose of study drug
Key Trial Info
Start Date :
August 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06966024
Start Date
August 27 2025
End Date
February 1 2029
Last Update
November 19 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
NEXT Austin
Austin, Texas, United States, 78758
2
NEXT Oncology
San Antonio, Texas, United States, 78229